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Abstract 
Background: Circulating microRNAs (miRNAs) are emerging as novel biomarkers for detecting cardiovascular 
diseases. In this study, we aimed to investigate the usefulness of miRNAs as biomarkers in diagnosing and predicting 
children with congenital heart defects (CHD), particularly in the context of multiple subtypes of CHD.
Methods: We recruited 26 families, each having a child with CHD and parents who do not have any cardiovascu-
lar disorder. 27 families unaffected by cardiovascular disease were also included as controls. Firstly, we screened 84 
circulating miRNAs relating to cardiovascular development in 6 children with atrial septal defects (ASD) and 5 healthy 
children. We validated the selected miRNAs with differential expression in a larger sample size (n = 27 for controls, 
n = 26 for cases), and evaluated their signal in different types of septal defects. Finally, we examined the identified 
miRNAs signatures in the parent population and assessed their diagnostic values for predicting CHD.
Results: The three miRNAs hsa-let-7a, hsa-let-7b and hsa-miR-486 were significantly upregulated in children with 
ASD. A further validation study showed that overexpression of hsa-let-7a and hsa-let-7b was specifically present in 
ASD children, but not in children with other subtypes of septal defects. A similar expression profile of hsa-let-7a and 
hsa-let-7b was discovered in mothers of ASD children. Receiver-operating characteristic curve analyses indicated that 
hsa-let-7a and hsa-let-7b had significant diagnostic values for detecting ASD and in maternal samples predicting the 
occurrence of ASD in offspring.
Conclusions: Circulating miRNAs are important markers not only for diagnosing CHD, but also for predicting CHD 
risk in offspring. The distinct miRNA signatures are likely to present in various subtypes of CHD, and the phenotypic 
heterogeneity of CHD should be considered to develop such miRNA-based assays.
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Background
With an incidence of approximately 1% in neonates, 
congenital heart defects (CHD) are the most common 
human congenital anomaly [1–3]. Such defects account 
for over 40% of prenatal deaths and over 20% of mortal-
ity in the first few months after birth [4]. CHD comprise 
a spectrum of pathology including septal defects, valve 
defects and lesions affecting the outflow tract. To date, 
approximately 20% of CHD cases are attributed to known 
causes such as genetic syndromes and teratogens, but 
very little is known about the aetiology of the remainder 
of cases (about 80%) [5]. This unknown aetiology of CHD 
follows a multifactorial inheritance model, implicating 
both genetic and environmental factors in disease devel-
opment [5].
An accurate and early diagnosis of CHD is of great 
significance for timely surgical intervention and effec-
tive postnatal management. With the advent of pediatric 
echocardiography, accurate detection of children with 
CHD has significantly improved. However, it remains a 
challenge to use as a screening tool, particularly during 
routine prenatal care, with detection rates ranging from 
6 to 53% due to lack of standardization [6, 7]. Therefore, 
development of a rapid and accurate diagnostic assay is 
imperative for clinical management and screening of 
CHD.
MicroRNAs (miRNAs) are small non-coding RNA 
strands that regulate the expression of genes at the post-
transcriptional and translational levels. These small non-
coding RNA molecules have emerged as key regulators 
in embryonic heart development, morphogenesis of the 
heart, and myocardial cell growth and differentiation 
[8]. In 2008, miRNAs were discovered to be present in 
plasma and serum with surprising stability [9]. Subse-
quently, several groups have reported on the use of miR-
NAs as circulating biomarkers for diagnosis or prognosis 
of cardiovascular diseases [10, 11], cancers [12, 13] and 
diabetes [14, 15], demonstrating that circulating miRNAs 
are quite specific for disease pathologies. Particularly in 
relation to congenital anomalies, Zhu et  al. identified 4 
miRNAs that were significantly up-regulated in moth-
ers carrying foetuses with CHD [16]. In children with 
congenital heart malformations with ventricular septal, 
8 miRNAs were dysregulated [17], while in adults with 
complete transposition of the great arteries after atrial 
switch operation, 11 miRNA expression signatures in 
serum were discovered, with miR-18a and miR-486-5p 
being associated with systemic ventricular contractility 
[18].
These first studies show the importance of specific 
miRNAs in CHD pathogenesis, and highlight the poten-
tial of circulating miRNAs as non-invasive biomarkers 
for detecting CHD. Nevertheless, different types of CHD 
possess different molecular alterations and possibly dif-
ferent miRNA signatures. Thus we hypothesised that 
specific miRNAs were associated with each subtype of 
congenital anomaly and that the phenotypic heterogene-
ity should be considered when identifying novel miRNA 
biomarkers and designing a sensitive diagnostic test. For 
the first part of this study we specifically selected chil-
dren with septal defects (one of main types of CHD), but 
without genetic syndromes to evaluate the diagnostic 
values of the circulating miRNAs in the subtypes of sep-
tal defects (atrial septal defects, ASD; ventricular septal 
defects, VSD; atrioventricular septal defects, AVSD) in 
which there are pathologic and morphologic similarities. 
It is reported that non-syndromic CHD patients often 
inherit abnormal epigenetic modifications from their 
seemingly healthy parents [19]. On the other hand, miR-
NAs are believed to regulate the epigenetic machinery 
[20], and the regulatory effect of miRNAs is a heritable 
genetic trait in humans [21]. We further hypothesised 
that the selected miRNAs could be used as biomarkers 
to predict occurrence of CHD in offspring. The subse-
quent aim of this study was to investigate the differential 
expression of the specific miRNAs in unaffected parents 
of children with/without CHD, and assess whether the 
miRNA levels could discriminate parents of CHD cases 
from parents of normal subjects.
Methods
Participant recruitment
From October 2014 to July 2016, we recruited 26 children 
with CHD as confirmed by ultrasound technique and 27 
age and gender matched healthy children as controls. The 
26 CHD cases consisted of ASD (n = 12), VSD (n = 8) 
and AVSD (n = 6). We collected blood samples from the 
parents of these participants, 44 for the case group (25 
mothers and 19 fathers) and 39 for the control group (23 
mothers and 16 fathers). All parents in the study were 
healthy subjects without any cardiovascular disease.
The study was approved by the Human Research Ethics 
Committee at Princess Margaret Hospital for Children, 
Western Australia (HREC Approval No: 2014095EP). 
Participants were recruited from Princess Margaret 
Hospital in Perth, Western Australia as part of the Kids 
Heart Research DNA bank program; a biobank for chil-
dren affected with CHD. Children with molecularly 
proven or clinically recognizable chromosomal or genetic 
syndromes causing CHD or other heart defects were 
excluded, as well as non-English speaking parents and 
pregnant mothers. A genetic counselor informed the 
families of the study parameters, gave them a study infor-
mation package and obtained informed consent from the 
families that agreed to participate in the study.
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Blood sample collection and plasma preparation
Three to 5 ml peripheral whole blood samples were col-
lected from each participant and centrifuged at 1200g 
for 10 min at 4 °C to remove the blood cells. The super-
natant was transferred into microcentrifuge tubes, fol-
lowed by a second centrifugation at 12,000g for 10 min at 
4  °C to completely remove cellular components. Plasma 
was then aliquoted and stored at −  80  °C until miRNA 
isolation.
Circulating miRNA extraction and cDNA synthesis
The total RNA in 50  μl plasma was mixed with QIA-
zol Lysis Reagent at a 1:5 ratio with C. elegans miR-39 
miRNA mimic as a Spike-In Control (Qiagen Pty, Don-
caster, VIC, Australia). The RNA was then extracted with 
the miRNeasy Serum/Plasma Kit (Qiagen), according 
to the manufacturer’s protocols. Purified RNA was con-
verted into cDNA using miScript II RT Kit (Qiagen).
miRNA PCR array assay
Six children with ASD and five controls were selected 
for the profiling of 84 circulating miRNAs. The miS-
cript miRNA PCR Array for Human Cardiovascular Dis-
ease (Qiagen) was used according to the manufacturer’s 
instructions. This miRNA Array profiles the expression 
of 84 miRNAs known to exhibit altered expression dur-
ing cardiovascular disease and development. PCR reac-
tions were performed using the ViiA 7 Real-Time PCR 
System (Thermo Fisher Scientific, Scoresby, VIC, Aus-
tralia). The reaction mixtures were incubated at 95 °C for 
15  min to activate the HotStart DNA Taq polymerase, 
followed by 40 cycles of 94 °C for 15 s, 55 °C for 30 s and 
70 °C for 30 s. The relative expression of each miRNA was 
normalised by the internal spike-in control Ce-miR-39. 
The microarray data were analysed using the miScript 
miRNA PCR Array Data Analysis Web Portal (http://
pcrda taana lysis .sabio scien ces.com/mirna /array analy sis.
php) (Qiagen).
Quantitative real‑time PCR (qPCR)
Three miRNAs (hsa-let-7a, hsa-let-7b and hsa-miR-486) 
were selected from the miRNA array screening based on 
the significant difference (p value) as well as fold change 
between case and control. These miRNAs were further 
examined using qPCR in all 53 children (including the 
children participating in the miRNA PCR array study) 
and their parents (n  =  83). miScript mature miRNA 
primer assays  (Cat# MS00031220, MS00003122 and 
MS00004284, Qiagen) were used for targeting the spe-
cific sequences of hsa-let-7a, hsa-let-7b and hsa-miR-486 
respectively. The PCRs were run using a miScript Syber 
green PCR master mix (Qiagen) and carried out as 
described above with the following annealing tempera-
tures: 55  °C for hsa-let-7a, 57  °C for hsa-let-7b, 60  °C 
for hsa-miR-486 and housekeeping miRNA Cel-miR-39. 
The specificity of amplification was verified using melt-
ing curve analysis. The expression levels of miRNAs were 
normalized against Ce-miR-39 using the  2−ΔΔCT method, 
and were presented relative to values in the children or 
parent control group.
Statistical analysis
Sigmaplot (version 11.0, Systat Software Inc, San Jose, 
USA) was used for statistical analysis. The independent T 
test was used to compare differences between two groups 
(control and CHD), whilst differences among multiple 
groups (control, ASD, VSD, AVSD) were assessed using 
one-way ANOVA, with a Tukey honestly significant dif-
ference test implemented as post hoc analysis. Correla-
tions of miRNA expression between children and their 
parents were analysed using the Pearson correlation 
method. Data are presented as mean (SD) or median 
(range). In addition, receiver-operating characteristic 
(ROC) curves were generated for the selected miRNAs 
to determine their clinical utility as diagnostic biomark-
ers using the statistical package SPSS (version 20.0: SPSS 
Inc., Chicago, IL, USA). Specifically, the area under the 
ROC curve (AUC) was measured by computing sensitiv-
ity and specificity for each possible cut-off point of the 
selected miRNA expression levels. The cut-off value was 
determined for each individual marker to maximize the 
classification accuracy according to the Youden index 
[22]. Statistical significance was accepted as p < 0.05.
Results
Participant’s characteristics
The participants’ demographic data are listed in Table 1. 
There was no significant difference in general charac-
teristics between the two groups (cases and controls) of 
children including age and gender. The parental age was 
also the similar between the case and control groups.
Table 1 Demographic data for the participants 
in the study
Data are presented as n or mean (SD)
Control group Disease group p value
Children’s population
 Male:female 12:18 18:8 0.29
Age (years) 7.87 ± 5.27 5.15 ± 0.50 0.58
Parent population
Maternal:paternal 23:14 25:20 0.546
Maternal age (years) 39.15 ± 7.38 36.72 ± 6.99 0.23
Paternal age (years) 39.46 ± 7.15 37.84 ± 5.88 0.39
Page 4 of 11Song et al. J Transl Med  (2018) 16:42 
Selection of candidate miRNA biomarkers
Out of the 84 miRNAs that were examined (Fig.  1a), 
the expressions of hsa-let-7a and hsa-miR-486 were sig-
nificantly up-regulated in children with ASD (p  <  0.05) 
compared to the controls. We also observed a mar-
ginal increase of the hsa-let-7b level (p =  0.092), which 
was increased more than twofold for the disease group 
(Fig. 1b). Although hsa-miR-494 expression was up-reg-
ulated in case children by approximately 3.6-fold (95% 
CI 0.00001, 13.69) relative to the controls, such differ-
ence was not significant (p =  0.389) since hsa-miR-494 
change was highly variable in the case group. No sig-
nificant differences in the other plasma miRNA levels 
were identified between the cases and healthy controls 
(p > 0.05). The three miRNAs (hsa-let-7a, hsa-let-7b and 
hsa-miR-486) were selected for further analysis.
Validation of the miRNA signatures in the children 
population
We examined the biomarker potential of the selected 
three miRNAs using the full cohort of children (26 cases, 
27 controls). Compared to the children of the control 
group, children with CHD (including the three types of 
septal defects) demonstrated a significantly higher level 
of hsa-let-7b and hsa-miR-486, whilst hsa-let-7a level did 
not show a significant difference between the two groups 
(Fig. 2). After stratifying by disease phenotype and com-
pared to the children from the control group, children 
Fig. 1 miRNA screening and selection: Eight four miRNA expression fold changes in six children with ASD (relative to five healthy children) were 
shown in scatter plot (a). The three miRNAs with high up-regulation were selected and shown in box plot (b). Box and whisker plots represent 
median with 10th and 90th centiles. miRNA microRNA, ASD atrial septal defects
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with ASD were found to have a higher expression of hsa-
let-7a (p = 0.002) and hsa-let-7b (p < 0.001) (Fig. 2a, b) 
while the hsa-miR-486 level was significantly higher for 
all ASD, VSD and AVSD groups (Fig. 2c).
We further evaluated hsa-let-7a, hsa-let-7b and hsa-
miR-486 for their ability to differentiate between healthy 
children and CHD children or specifically children with 
ASD using ROC curve analysis. As shown in Table  2, 
irrespective of CHD phenotype, only hsa-miR-486 
showed a significant diagnostic ability with AUC value 
of 0.755 (p = 0.002), sensitivity of 69% and specificity of 
70% (cut-off value: 1.39). When combining all three miR-
NAs, the AUC was slightly increased to a value of 0.783 
(p = 0.001). When applying the ROC analyses to detect 
children with ASD (Fig. 3), a significant improvement of 
diagnostic accuracy was revealed for hsa-let-7a and hsa-
let-7b, with AUC values of 0.833 (95% CI 0.641–1.000, 
p  =  0.002) and 0.900 (95% CI 0.764–1.000, p  <  0.001). 
The optimal diagnostic sensitivity and specificity were 70 
and 100% for hsa-let-7a with a cut-off expression value 
4.94, and 91 and 90% for hsa-let-7a with a cut-off expres-
sion value 2.30 respectively. Combining the different 
Fig. 2 Validation of the miRNA signatures in children population: comparison of hsa-let-7a (a), hsa-let-7b (b) and hsa-miR-486 (c) expression 
between children with CHD (n = 26) and healthy controls (n = 27). CHD phenotype is further stratified into ASD (n = 12), VSD (n = 8) and AVSD 
(n = 6) in comparison with the controls. Box and whisker plots represent median with 10th and 90th centiles. miRNA microRNA, CHD congenital 
heart defects, ASD atrial septal defects, VSD ventricular septal defects, AVSD atrioventricular septal defects
Table 2 ROC curve analysis showing the discriminative power of the selected microRNAs (miRNA) or the combined form 
in children and maternal populations
ROC receiver-operating characteristic, AUC area under an ROC curve, CHD congenital heart defects, including the three types of septal defects, ASD atrial septal 
defects, CI confidence interval
Population Phenotype miRNA AUC 95% CI p value
Children CHD hsa-let-7a 0.544 0.368–0.720 0.601
hsa-let-7b 0.656 0.486–0.816 0.063
hsa-miR-486 0.755 0.622–0.888 0.002
All three combined 0.783 0.653–0.912 0.001
Children ASD hsa-let-7a 0.833 0.641–1.000 0.002
hsa-let-7b 0.900 0.764–1.000 < 0.001
hsa-miR-486 0.806 0.516–0.895 0.068
All three combined 0.877 0.700–1.000 0.001
Mother ASD hsa-let-7a 0.917 0.822–1.000 < 0.001
hsa-let-7b 0.680 0.482–0.877 0.097
hsa-miR-486 0.562 0.297–0.827 0.567
hsa-let-7a/hsa-let-7b 0.909 0.810–1.000 0.050
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miRNAs did not further improve the diagnostic accuracy 
(Table 2).
Further investigation of the miRNA signatures 
in the parent population
Similarly, parents of CHD children had a higher level of 
circulating hsa-let-7a, hsa-let-7b and hsa-miR-486 com-
pared to parents of healthy children (p  <  0.05, data not 
shown). After stratifying by gender (Fig.  4), the differ-
ences remained significant for hsa-let-7a (p < 0.001) and 
hsa-let-7b ((p =  0.009) in the maternal population, and 
for hsa-miR-486 in the paternal population (p  =  0.03). 
Further stratification by disease subtype showed that 
mothers of ASD children had a 3.8-fold increase in 
hsa-let-7a, compared to mothers with healthy children 
(p  <  0.001, Fig.  4a). No other significant difference was 
observed between the subtype groups and controls for 
the three miRNA expressions.
ROC curve analysis (Fig.  5a) showed that hsa-let-7a 
had the best diagnostic performance with an AUC of 
0.917 (95% CI 0.822–1.000, p < 0.001; Table 2). At a cut-
off of 2.42, the hsa-let-7a level could distinguish between 
mothers with ASD offspring and mothers of healthy chil-
dren, with a sensitivity of 82% and a specificity of 91%. 
The other two miRNAs or combined miRNAs did not 
demonstrate a significant or better discriminative value 
(Fig. 5b and Table 2).
Correlation of the miRNA expression in children and parent 
populations
As shown in Fig.  6, there was a significant correlation 
between hsa-let-7a levels in children and their mothers 
 (R2 = 0.315, p < 0.001), while a marginal correlation was 
identified for hsa-let-7b levels  (R2  =  0.078, p  =  0.058). 
Hsa-miR-486 levels did not show a significant correla-
tion between these two populations. In addition, we did 
not observe any significant associations of the miRNAs 
between the children and their fathers.
Discussion
Through the screening of plasma miRNAs associated 
with cardiovascular development, we identified three 
miRNAs (hsa-let-7a, hsa-let-7b and hsa-miR-486) that 
were significantly upregulated in children with ASD. A 
further validation study showed that the overexpression 
of hsa-let-7a and hsa-let-7b was specifically present in 
children with ASD. ROC curve analyses suggested that 
both hsa-let-7a and hsa-let-7b had a significant diag-
nostic value for detecting ASD. Interestingly, a similar 
miRNA expression profile of hsa-let-7a and hsa-let-7b 
was discovered in the mothers of children with ASD and 
other types of CHD. Hsa-let-7a showed a high accuracy 
to distinguish mothers of offspring with ASD from moth-
ers with healthy children. We conclude, therefore, that 
circulating miRNAs are highly feasible as biomarkers for 
Fig. 3 Analysis of the discriminatory power of the miRNAs in children population: the graph shows the ROC curve analysis of the validation study 
for hsa-let-7a, hsa-let-7b and hsa-miR-486 (a) and the combination of the three miRNAs (b) in discriminating patients with ASD from healthy 
controls. miRNA microRNA, ROC receiver-operating characteristic, AUC area under the ROC curve, ASD atrial septal defects
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clinical detection of CHD, and may be powerful and use-
ful molecular tools for evaluating the risk of CHD in the 
next generation.
To our knowledge, there is paucity of data on the 
expression profile of circulating miRNAs in congenital 
heart malformations with ASD. Li et al. reported the up-
regulation of miR-498 and down-regulation of miR-let- 
7e-5p, miR-155-5p, miR-222-3p, miR379-5p, miR-433, 
and miR-487b, and miR-409-3p in plasma of pediatric 
patients with VSD [17]. Our newly identified three miR-
NAs are different from these molecules and we specu-
late that they are specific to the subtype of CHD. In this 
regard, we further examined the expression pattern of the 
three selected miRNAs in a larger sample size of children 
with ASD as well as children with VSD and VASD. Our 
data indicated that hsa-let-7a and hsa-let-7b were specifi-
cally upregulated in children with ASD, but not in chil-
dren with VSD or AVSD, supporting our first hypothesis 
that specific miRNAs are associated with specific types of 
CHD. Such difference should be not so surprised as hsa-
let-7a and hsa-let-7b were selected from miRNA array 
analysis using ASD samples. In contrast, a significant 
overexpression of hsa-miR-486 was observed in children 
with ASD, VSD or AVSD compared to the control chil-
dren, indicating that hsa-miR-486 may be involved in a 
common molecular pathway that regulates the pathogen-
esis of different CHD types. This finding is in agreement 
with the notion that clinically distinct malformations can 
arise from single genetic defects, and unrelated cardiac 
structures are likely to share similar developmental path-
ways [23].
In analysing the diagnostic values of the three miR-
NAs using ROC curve analysis, we confirmed that hsa-
miR-486 was a superior marker compared to hsa-let-7a 
and hsa-let-7b in diagnosing mixed phenotype CHD 
with an AUC value of 0.755 (sensitivity: 69%, specific-
ity: 70%). Similarly, without considering the phenotypic 
heterogeneity of CHD, Zhu et al. identified four miRNAs 
Fig. 4 Differential expression of the miRNA signatures in parent population: Comparison of hsa-let-7a (a), hsa-let-7b (b) and hsa-miR-486 (c) 
expression between parent with and without CHD children, stratified by gender: maternal (a–c) and paternal (d–f) populations. CHD phenotype 
is further stratified into ASD (n = 12 for maternal group; n = 9 for paternal group), VSD (n = 7 for maternal group; n = 6 for paternal group) and 
AVSD (n = 6 for maternal; n = 4 for paternal group) in comparison with the control parents (n = 23 for maternal group; n = 16 for paternal group). 
Box and whisker plots represent median with 10th and 90th centiles. miRNA microRNA, CHD congenital heart defects, ASD atrial septal defects, VSD 
ventricular septal defects, AVSD atrioventricular septal defects
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Fig. 5 Analysis of the discriminatory power of the miRNAs in maternal population: the graph shows the ROC curve analysis of the three selected 
miRNAs (hsa-let-7a, hsa-let-7b and hsa-miR-486) (a) and the combination of hsa-let-7a and hsa-let-7b (b) in discriminating mothers with ASD 
children from mothers with healthy children. miRNA microRNA, ROC receiver-operating characteristic, AUC area under the ROC curve, ASD atrial 
septal defects
Fig. 6 Association of hsa-let-7a/hsa-let-7b expression between children and maternal populations: A linear regression is established between 
expression levels of hsa-let-7a (solid circle)/hsa-let-7b (open circle) between children and maternal populations
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(miR-19b, miR-22, miR-29c and miR-375) as biomark-
ers for the prenatal detection of fetal CHD, with AUC 
of 0.671–0.790 and sensitivity and specificity ranges 
55.6–74.1% and 66.7–88.9% respectively [16]. Curti 
et  al. reported AUC values of 0.503–0.804 using mater-
nal plasma mRNA species for predicting fetal CHD with 
a detection rate of 66.7% and a false positive rate of 10% 
[24]. These reported diagnostic performances are com-
parable to our current finding for hsa-miR-486 as a com-
mon CHD marker. However, when we considered the 
specific types of CHD, we observed a significant improve-
ment in discriminatory power, particularly by using hsa-
let-7a and hsa-let-7b for detecting ASD patients. The 
ROC curve yielded an AUC value of 0.833 and a diagnos-
tic sensitivity and specificity of 70 and 100% for hsa-let-
7a, and AUC value of 0.900 and a diagnostic sensitivity 
and specificity of 91 and 90% for hsa-let-7b. These higher 
accuracy levels show that using specific biomarkers for 
CHD subtypes in clinical detection is necessary.
The parent-of-origin was proposed to be the etiological 
mechanism of CHD in children, including genetic/epige-
netic and environmental influences [5]. The recent study 
performed in non-syndromic children CHD revealed 
significant enrichment of protein-truncating variants 
inherited from unaffected parents in CHD-associated 
genes [19]. One study even showed that the risk of CHD 
in children could be attributed to grandparents with 
cardiovascular disease [25]. In addition to the genetic 
influence, environmental factors in particular maternal 
lifestyle are highly related to risk of CHD. These include 
maternal smoking, alcohol, illicit drugs use, caffeine use, 
body mass index and psychological factors [26]. Con-
cerning the underlying mechanisms of CHD, it is widely 
accepted that miRNAs play a critical role in regulating 
the pathogenesis of CHD. An increasing number of stud-
ies have shown that miRNAs also interactively regulate 
two other inheritable epigenetic components, namely 
DNA methylation and histone modification, to consti-
tute an inter-regulatory system that assures an accurate 
transcriptional and translational expression of protein-
coding genes [20]. In addition, the genetic differences in 
the overall efficiency of the miRNA biogenesis pathway 
were found between individuals, which were correlated 
to their parents [21]. As such, we reasonably speculate 
that miRNA signatures can be used as a genetic coun-
seling tool to evaluate an individual’s risk of having CHD-
affected offspring. Subsequently, we investigated the 
diagnostic values of these miRNAs for predicting CHD 
in offspring using parent–offspring trios. In these unaf-
fected (healthy) parents, we observed similar changes 
in expression patterns, in hsa-let-7a and hsa-let-7b for 
mothers of probands, and in hsa-miR-486 for fathers of 
probands. ROC curve analyse showed a high accuracy 
of the hsa-let-7a level for differentiating mothers of chil-
dren with ASD from mothers of healthy children (AUC: 
0.917; sensitivity: 82%; specificity: 91%). A further corre-
lation study demonstrated a positive association of hsa-
let-7a and hsa-let-7b between children and their mothers. 
These data indicate that maternal effects are a major 
factor contributing to CHD development in the current 
cohort. The abnormal expression of hsa-miR-486 in the 
fathers of CHD children may be indicative of a paternal 
effect on the disease development. One important limita-
tion of the present study is that we cannot ascertain the 
specific parental origin of the patients (maternal or pater-
nal) and cause (genetic or environmental). This limits the 
data interpretation and hinders an accurate assessment 
of the predictive values. However, our data clearly sug-
gest that miRNA signatures are promising biomarkers for 
determining the risk of CHD in offspring.
Interestingly, the let-7 family of circulating miRNAs 
is regarded as a mediator of intercellular communica-
tion [27]. In acute myocardial infarction (AMI) patients, 
let-7b is dramatically inhibited during the disease onset 
and of significant diagnostic value for AMI [28]. The 
circulating miR-486 regulation was found to depend on 
the tricuspid or bicuspid morphology of the aortic valve 
[29]. According to DIANA TOOLS [30], both let-7a and 
let-7b negatively regulate HAND1 mRNA with a miTG 
predictive score from 0.99 to 1.00. HAND1 governs the 
development of various tissues within the embryo, the 
extraembryonic mesoderm and trophectoderm. It is 
likely that the overexpression of let-7a and let-7b inhib-
its HAND1 and disrupts cardiac embryogenesis, which 
makes them promising diagnostic targets in detecting 
ASD. The downstream targets of miR-486 are predicted 
to be the PTEN and FOXO1 genes. Both gene coding 
products are involved in the PI3-kinase/Akt signaling 
pathway, and consequently miR-486 is thought to regu-
late PI3-kinase/Akt signaling to cause muscle hyper-
trophic growth [31, 32]. Intriguingly, dysregulation of 
these miRNAs has not resulted in heart defects in the 
parental population, indicating that the functional effects 
of these miRNAs may depend on the critical develop-
ment stages e.g. antenatal development. It is worthy of 
further investigation for understanding the fundamental 
mechanisms of CHD development.
Conclusion
Overall, we identified a consistent expression pattern 
of circulating hsa-let-7a and hsa-let-7b in children with 
ASD and their mothers. These non-coding molecules in 
plasma are useful to diagnose children with ASD, and 
hsa-let-7a is a promising biomarker for evaluating the 
risk of ASD in offspring. Our data support the potential 
of using circulating miRNAs as diagnostic and genetic 
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screening markers for CHD. However, the sample size 
is small in the present study, particularly after stratify-
ing by CHD phenotype. Large-scale studies are needed 
to replicate our results and further validate the candi-
date biomarker specificity by including other cardiovas-
cular diseases. Additionally, it is of great interest to test 
the suitability of these markers for prenatal screening 
or prognosis evaluation of CHD. Finally, in light of our 
findings, we strongly recommend that specific miRNAs 
should be explored in each type of CHD and the multiple 
specific miRNAs should be ultimately combined into one 
biomarker panel to aid in the clinical diagnosis, screening 
and prediction of CHD.
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